Oppenheimer Maintains Outperform on Ventyx Biosciences, Raises Price Target to $60
Oppenheimer analyst Jeff Jones maintains Ventyx Biosciences (NASDAQ:VTYX) with a Outperform and raises the price target from $55 to $60.
Goldman Sachs Initiates Coverage On Ventyx Biosciences with Buy Rating, Announces Price Target of $50
Goldman Sachs analyst Chris Shibutani initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Buy rating and announces Price Target of $50.
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers OpGen (NASDAQ:OPGN) stock rose 69.6% to $0.21 during Tuesday’s pre-market session. The market value of their outstanding…
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
Gainers
Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million.
Morgan Stanley Initiates Coverage On Ventyx Biosciences with Overweight Rating, Announces Price Target of $45
Morgan Stanley analyst Simon Flannery initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Overweight rating and announces Price Target of $45.
Ventyx Biosciences Q3 EPS $(0.59) Misses $(0.44) Estimate
Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.44) by 34.09 percent. This is a 81.39 percent increase over losses of $(3.17) per share
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.